Abzena has completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect (antibody conjugation) and HydraSpace (highly polar spacer). Familiarity with these antibody-drug conjugate (ADC) technologies adds to Abzena’s expertise in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Synaffix technology with high scientific quality.
 
“Abzena believes in patient first drug development,” said Jonathan Goldman, chief executive officer, Abzena. “Our expertise and experience with Synaffix GlycoConnect and HydraSpace technology further advances our leadership across multiple platforms in ADC. We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development.”